

Supplementary Table S2. Serum anti-spike IgA and IgG levels.

| | IgG | IgA |
|-------------------------------------|----------------------------|---------------|
| SARS-CoV-2 NI (n=6) | 0.2 (0.1-0.4) ¹ | 0.4 (0.1-0.8) |
| Vaccinated HU (n=61) | 8.6 (7.7-9.5) | 7.4 (4.5-8.4) |
| Vaccinated HIV (n=50) | 8.0 (7.2-8.8) | 5.8 (2.9-8.3) |
| COVID HU (n=17) | 3.9 (2.6-6.0) | 4.0 (2.5-7.6) |
| COVID HIV (n=26) | 3.9 (2.2-6.6) | 3.2 (1.5-6.7) |
| P value vaccinated vs. COVID | | |
| HU | <0.0001 | 0.023 |
| HIV | <0.0001 | 0.086 |
| P value HU vs. HIV | | |
| Vaccinated | 0.028 | 0.077 |
| COVID | 0.816 | 0.522 |

¹ Shown are medians with IQRs in brackets of serum anti-spike IgG and IgA ratios. NI: non-immune, HU: HIV-1-uninfected. HIV: HIV-1-infected. A ratio of <0.8 was considered as negative, a ratio of 0.8-1.1 as borderline and ≥1.1 as positive. Significance was tested by Mann-Whitney-U test. All vaccinated and convalescent groups had significantly higher IgG- (p≤0.0001) and IgA-ratios (p≤0.0009) compared to the NI group.